Inactive Ingredient Search for Approved Drug Products
Search Names Beginning with B
Inactive Ingredient | Route | Dosage Form | CAS Number | UNII | Maximum Potency per unit dose | Maximum Daily Exposure (MDE) | Record Updated |
---|---|---|---|---|---|---|---|
BALSAM PERU | RECTAL | SUPPOSITORY | 8007009 | 8P5F881OCY | 100mg | ||
BARIUM SULFATE | INTRAUTERINE | SUPPOSITORY, EXTENDED RELEASE | 7727437 | 25BB7EKE2E | 10mg | ||
BARIUM SULFATE | SUBCUTANEOUS | IMPLANT | 7727437 | 25BB7EKE2E | 15mg | ||
BEEF TALLOW | ORAL | CAPSULE, EXTENDED RELEASE | 61789977 | 98HPY76U4W | 12.4mg | ||
BENTONITE | DENTAL | POWDER, DENTIFRICE | 1302789 | A3N5ZCN45C | 0.05mg/mg | ||
BENTONITE | ORAL | CAPSULE | 1302789 | A3N5ZCN45C | ADJ PH | ||
BENTONITE | ORAL | SUSPENSION | 1302789 | A3N5ZCN45C | 65mg/5ml | ||
BENTONITE | ORAL | TABLET | 1302789 | A3N5ZCN45C | 355mg | ||
BENTONITE | ORAL | TABLET, COATED | 1302789 | A3N5ZCN45C | 1.8mg | ||
BENTONITE | TOPICAL | CREAM | 1302789 | A3N5ZCN45C | 4.1%w/w | ||
BENTONITE | TOPICAL | LOTION | 1302789 | A3N5ZCN45C | 5%w/w | ||
BENTONITE | TOPICAL | POWDER | 1302789 | A3N5ZCN45C | 0.67mg/mg | ||
BENTONITE | TOPICAL | SHAMPOO, SUSPENSION | 1302789 | A3N5ZCN45C | 3.25%w/v | ||
BENTONITE | TRANSDERMAL | SYSTEM | 1302789 | A3N5ZCN45C | 9.86mg | ||
BENTONITE | VAGINAL | SUPPOSITORY | 1302789 | A3N5ZCN45C | 288.1mg | ||
BENZALDEHYDE | ORAL | LOZENGE | 100527 | TA269SD04T | 31mg | ||
BENZALDEHYDE | ORAL | SUSPENSION | 100527 | TA269SD04T | 0.6mg/1ml | ||
BENZALKONIUM CHLORIDE | AURICULAR (OTIC) | SOLUTION | 8001545 | F5UM2KM3W7 | 0.01%w/v | Y | |
BENZALKONIUM CHLORIDE | AURICULAR (OTIC) | SUSPENSION | 8001545 | F5UM2KM3W7 | 0.01%w/v | ||
BENZALKONIUM CHLORIDE | AURICULAR (OTIC) | SUSPENSION/ DROPS | 8001545 | F5UM2KM3W7 | 0.02%w/v | ||
BENZALKONIUM CHLORIDE | INTRA-ARTICULAR | INJECTION | 8001545 | F5UM2KM3W7 | 1mg | ||
BENZALKONIUM CHLORIDE | INTRALESIONAL | INJECTION | 8001545 | F5UM2KM3W7 | 1mg | ||
BENZALKONIUM CHLORIDE | INTRAMUSCULAR | INJECTION | 8001545 | F5UM2KM3W7 | 1mg | ||
BENZALKONIUM CHLORIDE | NASAL | LIQUID | 8001545 | F5UM2KM3W7 | 0.2mg/1ml | ||
BENZALKONIUM CHLORIDE | NASAL | SOLUTION | 8001545 | F5UM2KM3W7 | 40.46mg/100ml | ||
BENZALKONIUM CHLORIDE | NASAL | SPRAY | 8001545 | F5UM2KM3W7 | 1mg | ||
BENZALKONIUM CHLORIDE | NASAL | SPRAY, METERED | 8001545 | F5UM2KM3W7 | 1mg | Y | |
BENZALKONIUM CHLORIDE | OPHTHALMIC | GEL | 8001545 | F5UM2KM3W7 | 0.01%w/w | ||
BENZALKONIUM CHLORIDE | OPHTHALMIC | SOLUTION | 8001545 | F5UM2KM3W7 | 2%w/v | ||
BENZALKONIUM CHLORIDE | OPHTHALMIC | SOLUTION/ DROPS | 8001545 | F5UM2KM3W7 | 0.03%w/v | ||
BENZALKONIUM CHLORIDE | OPHTHALMIC | SUSPENSION | 8001545 | F5UM2KM3W7 | 0.02%w/v | ||
BENZALKONIUM CHLORIDE | OPHTHALMIC | SUSPENSION/ DROPS | 8001545 | F5UM2KM3W7 | 0.02%w/v | ||
BENZALKONIUM CHLORIDE | RESPIRATORY (INHALATION) | SOLUTION | 8001545 | F5UM2KM3W7 | 0.02%w/w | ||
BENZALKONIUM CHLORIDE | TOPICAL | CLOTH | 8001545 | F5UM2KM3W7 | NA | ||
BENZALKONIUM CHLORIDE | TOPICAL | LOTION | 8001545 | F5UM2KM3W7 | 0.1%w/w | ||
BENZALKONIUM CHLORIDE | TOPICAL | OINTMENT | 8001545 | F5UM2KM3W7 | 0.03%w/w | ||
BENZALKONIUM CHLORIDE | TOPICAL | SHAMPOO | 8001545 | F5UM2KM3W7 | 0.2%w/w | ||
BENZALKONIUM CHLORIDE | TOPICAL | SOLUTION | 8001545 | F5UM2KM3W7 | 0.02%w/v | ||
BENZALKONIUM CHLORIDE | TOPICAL | SOLUTION/ DROPS | 8001545 | F5UM2KM3W7 | 0.01%w/v | ||
BENZALKONIUM CHLORIDE | TOPICAL | SUSPENSION/ DROPS | 8001545 | F5UM2KM3W7 | NA | ||
BENZENESULFONIC ACID | INTRAVENOUS | INJECTION | 98113 | 685928Z18A | ADJ PH | ||
BENZENESULFONIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 98113 | 685928Z18A | ADJ PH | ||
BENZENESULFONIC ACID | INTRAVENOUS | LIQUID | 98113 | 685928Z18A | ADJ PH | ||
BENZETHONIUM CHLORIDE | AURICULAR (OTIC) | SOLUTION | 121540 | PH41D05744 | 0.02%w/v | ||
BENZETHONIUM CHLORIDE | INTRAMUSCULAR | INJECTION | 121540 | PH41D05744 | 1mg | ||
BENZETHONIUM CHLORIDE | INTRAVENOUS | INJECTION | 121540 | PH41D05744 | 1mg | ||
BENZETHONIUM CHLORIDE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 121540 | PH41D05744 | 0.5mg | ||
BENZETHONIUM CHLORIDE | OPHTHALMIC | SOLUTION/ DROPS | 121540 | PH41D05744 | 0.02%w/w | ||
BENZETHONIUM CHLORIDE | TOPICAL | CREAM | 121540 | PH41D05744 | NA | ||
BENZOCAINE | TOPICAL | OINTMENT | 94097 | U3RSY48JW5 | 1%w/w | ||
BENZODODECINIUM BROMIDE | OPHTHALMIC | SOLUTION, GEL FORMING / DROPS | 7281041 | IRY12B2TQ6 | 0.01%w/v | Y | |
BENZODODECINIUM BROMIDE | OPHTHALMIC | SOLUTION, GEL FORMING, EXTENDED RELEASE | 7281041 | IRY12B2TQ6 | 0.01%w/w | ||
BENZOIC ACID | BUCCAL | MOUTHWASH | 65850 | 8SKN0B0MIM | NA | ||
BENZOIC ACID | INTRAMUSCULAR | INJECTION | 65850 | 8SKN0B0MIM | 5%w/v | ||
BENZOIC ACID | INTRAMUSCULAR | INJECTION, SOLUTION | 65850 | 8SKN0B0MIM | 0.2%w/v | ||
BENZOIC ACID | INTRAVENOUS | INJECTION | 65850 | 8SKN0B0MIM | 5%w/v | ||
BENZOIC ACID | IRRIGATION | SOLUTION | 65850 | 8SKN0B0MIM | 0.02%w/v | ||
BENZOIC ACID | ORAL | CONCENTRATE | 65850 | 8SKN0B0MIM | 12.5mg/5ml | ||
BENZOIC ACID | ORAL | ELIXIR | 65850 | 8SKN0B0MIM | 90mg | ||
BENZOIC ACID | ORAL | LIQUID | 65850 | 8SKN0B0MIM | 2mg/1ml | ||
BENZOIC ACID | ORAL | SOLUTION | 65850 | 8SKN0B0MIM | 100mg | ||
BENZOIC ACID | ORAL | SUSPENSION | 65850 | 8SKN0B0MIM | 15mg | ||
BENZOIC ACID | ORAL | SYRUP | 65850 | 8SKN0B0MIM | 20mg | ||
BENZOIC ACID | ORAL | TABLET, COATED | 65850 | 8SKN0B0MIM | NA | ||
BENZOIC ACID | ORAL | TABLET, FILM COATED | 65850 | 8SKN0B0MIM | NA | ||
BENZOIC ACID | RECTAL | GEL | 65850 | 8SKN0B0MIM | 11mg | ||
BENZOIC ACID | RECTAL | SUSPENSION | 65850 | 8SKN0B0MIM | 0.1%w/w | ||
BENZOIC ACID | TOPICAL | AEROSOL, FOAM | 65850 | 8SKN0B0MIM | 1mg | ||
BENZOIC ACID | TOPICAL | CREAM | 65850 | 8SKN0B0MIM | 6mg | ||
BENZOIC ACID | TOPICAL | GEL | 65850 | 8SKN0B0MIM | 0.1%w/w | ||
BENZOIC ACID | TOPICAL | LOTION | 65850 | 8SKN0B0MIM | 0.2%w/w | ||
BENZOIC ACID | TOPICAL | SOLUTION | 65850 | 8SKN0B0MIM | 0.1%w/w | ||
BENZOIC ACID | VAGINAL | AEROSOL, FOAM | 65850 | 8SKN0B0MIM | 0.1%w/w | ||
BENZOIC ACID | VAGINAL | CREAM | 65850 | 8SKN0B0MIM | 0.25%w/w | ||
BENZOIC ACID | VAGINAL | SUPPOSITORY | 65850 | 8SKN0B0MIM | 2mg | ||
BENZOIN RESIN | TOPICAL | OINTMENT | 9000059 | GK21SBA74R | NA | ||
BENZOIN, (+/-)- | ORAL | CAPSULE | 119539 | L7J6A1NE81 | NA | ||
BENZOIN, (+/-)- | ORAL | CAPSULE, EXTENDED RELEASE | 119539 | L7J6A1NE81 | NA | ||
BENZYL ALCOHOL | AURICULAR (OTIC) | SUSPENSION | 100516 | LKG8494WBH | 0.9%w/v | ||
BENZYL ALCOHOL | ENDOTRACHEAL | INJECTION | 100516 | LKG8494WBH | 54mg | ||
BENZYL ALCOHOL | EPIDURAL | INJECTION | 100516 | LKG8494WBH | 1%w/v | ||
BENZYL ALCOHOL | INTRA-ARTERIAL | INJECTION | 100516 | LKG8494WBH | 0.9%w/v | ||
BENZYL ALCOHOL | INTRA-ARTICULAR | INJECTION | 100516 | LKG8494WBH | 40mg | ||
BENZYL ALCOHOL | INTRA-ARTICULAR | INJECTION, SOLUTION | 100516 | LKG8494WBH | 23mg | ||
BENZYL ALCOHOL | INTRA-ARTICULAR | INJECTION, SUSPENSION | 100516 | LKG8494WBH | 40mg | ||
BENZYL ALCOHOL | INTRACAVITARY | INJECTION | 100516 | LKG8494WBH | 0.01ml | ||
BENZYL ALCOHOL | INTRACAVITARY | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100516 | LKG8494WBH | 8.4mg | ||
BENZYL ALCOHOL | INTRALESIONAL | INJECTION | 100516 | LKG8494WBH | 18mg | ||
BENZYL ALCOHOL | INTRALESIONAL | INJECTION, SUSPENSION | 100516 | LKG8494WBH | 19mg | Y | |
BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION | 100516 | LKG8494WBH | 1000mg | ||
BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, EMULSION | 100516 | LKG8494WBH | 225mg | ||
BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 100516 | LKG8494WBH | 144mg | ||
BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, SOLUTION | 100516 | LKG8494WBH | 500mg | ||
BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, SUSPENSION | 100516 | LKG8494WBH | 40mg | ||
BENZYL ALCOHOL | INTRAMUSCULAR | SOLUTION | 100516 | LKG8494WBH | 20mg | ||
BENZYL ALCOHOL | INTRASYNOVIAL | INJECTION, SUSPENSION | 100516 | LKG8494WBH | 18mg | ||
BENZYL ALCOHOL | INTRAVENOUS | INJECTION | 100516 | LKG8494WBH | 1620mg | ||
BENZYL ALCOHOL | INTRAVENOUS | INJECTION, EMULSION | 100516 | LKG8494WBH | 45mg | ||
BENZYL ALCOHOL | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 100516 | LKG8494WBH | 144mg | ||
BENZYL ALCOHOL | INTRAVENOUS | INJECTION, SOLUTION | 100516 | LKG8494WBH | 400mg | ||
BENZYL ALCOHOL | INTRAVENOUS | LIQUID | 100516 | LKG8494WBH | 1.04%w/v | ||
BENZYL ALCOHOL | INTRAVENOUS | SOLUTION | 100516 | LKG8494WBH | 242mg | ||
BENZYL ALCOHOL | NASAL | SPRAY | 100516 | LKG8494WBH | 5mg | ||
BENZYL ALCOHOL | NASAL | SPRAY, METERED | 100516 | LKG8494WBH | 5mg/1ml | ||
BENZYL ALCOHOL | ORAL | CAPSULE | 100516 | LKG8494WBH | 450mg | ||
BENZYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 100516 | LKG8494WBH | 1.23mg | ||
BENZYL ALCOHOL | ORAL | SOLUTION | 100516 | LKG8494WBH | 50mg/1ml | ||
BENZYL ALCOHOL | ORAL | SUSPENSION | 100516 | LKG8494WBH | 100mg | ||
BENZYL ALCOHOL | ORAL | TABLET | 100516 | LKG8494WBH | 1.06mg | ||
BENZYL ALCOHOL | ORAL | TABLET, DELAYED RELEASE | 100516 | LKG8494WBH | 2.31mg | ||
BENZYL ALCOHOL | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 100516 | LKG8494WBH | 1.25mg | ||
BENZYL ALCOHOL | RECTAL | GEL | 100516 | LKG8494WBH | 124mg | ||
BENZYL ALCOHOL | RECTAL | SUPPOSITORY | 100516 | LKG8494WBH | 129mg | ||
BENZYL ALCOHOL | SOFT TISSUE | INJECTION | 100516 | LKG8494WBH | 18mg | ||
BENZYL ALCOHOL | SOFT TISSUE | INJECTION, SUSPENSION | 100516 | LKG8494WBH | 40mg | ||
BENZYL ALCOHOL | SUBCONJUNCTIVAL | INJECTION | 100516 | LKG8494WBH | 252mg | ||
BENZYL ALCOHOL | SUBCUTANEOUS | INJECTION | 100516 | LKG8494WBH | 90mg | ||
BENZYL ALCOHOL | SUBCUTANEOUS | INJECTION, EMULSION | 100516 | LKG8494WBH | 225mg | ||
BENZYL ALCOHOL | SUBCUTANEOUS | INJECTION, SOLUTION | 100516 | LKG8494WBH | 0.95%w/v | ||
BENZYL ALCOHOL | TOPICAL | CREAM | 100516 | LKG8494WBH | 160mg | ||
BENZYL ALCOHOL | TOPICAL | CREAM, AUGMENTED | 100516 | LKG8494WBH | 1%w/w | ||
BENZYL ALCOHOL | TOPICAL | GEL | 100516 | LKG8494WBH | 185mg | ||
BENZYL ALCOHOL | TOPICAL | LOTION | 100516 | LKG8494WBH | 4000mg | Y | |
BENZYL ALCOHOL | TOPICAL | OINTMENT | 100516 | LKG8494WBH | 2.2%w/w | ||
BENZYL ALCOHOL | TOPICAL | SHAMPOO | 100516 | LKG8494WBH | 1.25%w/w | ||
BENZYL ALCOHOL | TOPICAL | SOLUTION | 100516 | LKG8494WBH | 2%w/w | ||
BENZYL ALCOHOL | TOPICAL | SUSPENSION | 100516 | LKG8494WBH | 1%w/w | ||
BENZYL ALCOHOL | VAGINAL | CREAM | 100516 | LKG8494WBH | 1%w/w | ||
BENZYL ALCOHOL | VAGINAL | SUPPOSITORY | 100516 | LKG8494WBH | NA | ||
BENZYL BENZOATE | INTRAMUSCULAR | INJECTION | 120514 | N863NB338G | 1500mg | ||
BENZYL BENZOATE | INTRAMUSCULAR | INJECTION, SOLUTION | 120514 | N863NB338G | 750mg | ||
BENZYL BENZOATE | INTRAMUSCULAR | SOLUTION | 120514 | N863NB338G | 447mg | ||
BENZYL BENZOATE | ORAL | CAPSULE | 120514 | N863NB338G | NA | ||
BENZYL CHLORIDE | INTRAVENOUS | INJECTION | 100447 | 83H19HW7K6 | NA | ||
BETA CAROTENE | ORAL | EMULSION | 7235407 | 01YAE03M7J | NA | ||
BETA CAROTENE | TOPICAL | CREAM | 7235407 | 01YAE03M7J | NA | ||
BETADEX | ORAL | TABLET | 7585399 | JV039JZZ3A | 133.33mg | ||
BETADEX | ORAL | TABLET, CHEWABLE | 7585399 | JV039JZZ3A | 85mg | ||
BETADEX | ORAL | TABLET, FILM COATED | 7585399 | JV039JZZ3A | 41.25mg | ||
BETADEX | TOPICAL | GEL | 7585399 | JV039JZZ3A | 20mg | ||
BETADEX SULFOBUTYL ETHER SODIUM | INTRAMUSCULAR | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 182410000 | 2PP9364507 | 883mg | ||
BETADEX SULFOBUTYL ETHER SODIUM | INTRAVENOUS | INJECTION | 182410000 | 2PP9364507 | 6574mg | ||
BETADEX SULFOBUTYL ETHER SODIUM | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 182410000 | 2PP9364507 | 19200mg | ||
BETADEX SULFOBUTYL ETHER SODIUM | INTRAVENOUS | INJECTION, SOLUTION | 182410000 | 2PP9364507 | 13333mg | ||
BETANAPHTHOL | ORAL | CAPSULE | 135193 | P2Z71CIK5H | 0.3mg | ||
BISMUTH SUBCARBONATE | ORAL | TABLET | 5892104 | M41L2IN55T | 4.35mg | ||
BISMUTH SUBCARBONATE | ORAL | TABLET, EXTENDED RELEASE | 5892104 | M41L2IN55T | 0.04mg | ||
BLACK CURRANT | ORAL | SOLUTION | 9755T40D11 | 213mg | |||
BLACK INK | ORAL | CAPSULE | NA | 1mg | |||
BLACK INK | ORAL | CAPSULE, DELAYED RELEASE | NA | 0.57mg | |||
BLACK INK | ORAL | CAPSULE, EXTENDED RELEASE | NA | 0.03mg | |||
BLACK INK | ORAL | CAPSULE, LIQUID FILLED | NA | NA | |||
BLACK INK | ORAL | TABLET | NA | 0.14mg | |||
BLACK INK | ORAL | TABLET, DELAYED RELEASE | NA | 1mg | |||
BLACK INK | ORAL | TABLET, EXTENDED RELEASE | NA | 3mg | |||
BLACK INK | ORAL | TABLET, FILM COATED | NA | 0.15mg | |||
BLACK INK | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | NA | NA | |||
BLACK INK | RESPIRATORY (INHALATION) | CAPSULE | NA | NA | |||
BLACK INK | RESPIRATORY (INHALATION) | POWDER | NA | NA | |||
BORIC ACID | AURICULAR (OTIC) | SOLUTION | 10043353 | R57ZHV85D4 | 0.05%w/w | ||
BORIC ACID | AURICULAR (OTIC) | SUSPENSION | 10043353 | R57ZHV85D4 | 0.6%w/v | ||
BORIC ACID | AURICULAR (OTIC) | SUSPENSION/ DROPS | 10043353 | R57ZHV85D4 | 3mg | ||
BORIC ACID | BUCCAL | MOUTHWASH | 10043353 | R57ZHV85D4 | 7.36mg/1ml | ||
BORIC ACID | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10043353 | R57ZHV85D4 | 0.53%w/v | ||
BORIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 10043353 | R57ZHV85D4 | 0.32%w/v | ||
BORIC ACID | OPHTHALMIC | DROPS | 10043353 | R57ZHV85D4 | 1%w/w | ||
BORIC ACID | OPHTHALMIC | EMULSION | 10043353 | R57ZHV85D4 | 0.3%w/v | ||
BORIC ACID | OPHTHALMIC | GEL | 10043353 | R57ZHV85D4 | 0.5%w/w | ||
BORIC ACID | OPHTHALMIC | SOLUTION | 10043353 | R57ZHV85D4 | 38mg | ||
BORIC ACID | OPHTHALMIC | SOLUTION, GEL FORMING, EXTENDED RELEASE | 10043353 | R57ZHV85D4 | 0.3%w/w | ||
BORIC ACID | OPHTHALMIC | SOLUTION/ DROPS | 10043353 | R57ZHV85D4 | 48mg | ||
BORIC ACID | OPHTHALMIC | SUSPENSION | 10043353 | R57ZHV85D4 | 0.25%w/v | ||
BORIC ACID | OPHTHALMIC | SUSPENSION/ DROPS | 10043353 | R57ZHV85D4 | 1%w/v | ||
BORIC ACID | TOPICAL | EMULSION | 10043353 | R57ZHV85D4 | 1.3%w/w | ||
BORIC ACID | TOPICAL | SHAMPOO | 10043353 | R57ZHV85D4 | 2%w/w | ||
BORIC ACID | TOPICAL | SOLUTION | 10043353 | R57ZHV85D4 | 1.24%w/v | ||
BORIC ACID | TOPICAL | SUSPENSION/ DROPS | 10043353 | R57ZHV85D4 | 0.3%w/v | ||
BORIC ACID | VAGINAL | JELLY | 10043353 | R57ZHV85D4 | 1%w/w | ||
BROWN IRON OXIDE | ORAL | CAPSULE | 52357707 | 1N032N7MFO | NA | ||
BROWN IRON OXIDE | ORAL | TABLET | 52357707 | 1N032N7MFO | 0.79mg | ||
BROWN IRON OXIDE | ORAL | TABLET, FILM COATED | 52357707 | 1N032N7MFO | 0.2mg | ||
BUTANE | RECTAL | AEROSOL, FOAM | 106978 | 6LV4FOR43R | 12mg | ||
BUTANE | TOPICAL | AEROSOL | 106978 | 6LV4FOR43R | NA | ||
BUTANE | TOPICAL | AEROSOL, FOAM | 106978 | 6LV4FOR43R | 27%w/w | ||
BUTYL ALCOHOL | ORAL | CAPSULE | 71363 | 8PJ61P6TS3 | 0.02mg | ||
BUTYL ALCOHOL | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 71363 | 8PJ61P6TS3 | NA | ||
BUTYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 71363 | 8PJ61P6TS3 | 0.01mg | ||
BUTYL ALCOHOL | ORAL | TABLET | 71363 | 8PJ61P6TS3 | 0.01mg | ||
BUTYL ALCOHOL | ORAL | TABLET, COATED | 71363 | 8PJ61P6TS3 | NA | ||
BUTYL ALCOHOL | ORAL | TABLET, DELAYED RELEASE | 71363 | 8PJ61P6TS3 | 0.05mg | ||
BUTYL ALCOHOL | ORAL | TABLET, EXTENDED RELEASE | 71363 | 8PJ61P6TS3 | NA | ||
BUTYL ALCOHOL | TOPICAL | SOLUTION | 71363 | 8PJ61P6TS3 | 0.08%w/w | ||
BUTYL ALCOHOL | TOPICAL | SWAB | 71363 | 8PJ61P6TS3 | 0.08%w/w | ||
BUTYL ESTER OF METHYL VINYL ETHER/MALEIC ANHYDRIDE COPOLYMER (125000 MW) | TOPICAL | SOLUTION | 25119680 | 389H2R62BD | 15%w/w | ||
BUTYL METHACRYLATE AND METHYL METHACRYLATE COPOLYMER (3:1; 150000 MW) | TRANSDERMAL | SYSTEM | 25608337 | DJN2FGG8Z3 | 18mg | ||
BUTYL STEARATE | TOPICAL | CREAM | 123955 | 6Y0AI5605C | 3.68%w/w | ||
BUTYL STEARATE | TOPICAL | LOTION | 123955 | 6Y0AI5605C | NA | ||
BUTYLATED HYDROXYANISOLE | INTRAVENOUS | INJECTION | 25013165 | REK4960K2U | NA | ||
BUTYLATED HYDROXYANISOLE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 25013165 | REK4960K2U | NA | ||
BUTYLATED HYDROXYANISOLE | INTRAVENOUS | INJECTION, SOLUTION | 25013165 | REK4960K2U | NA | ||
BUTYLATED HYDROXYANISOLE | NASAL | SOLUTION | 25013165 | REK4960K2U | 20mg/100ml | ||
BUTYLATED HYDROXYANISOLE | ORAL | CAPSULE | 25013165 | REK4960K2U | 4mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | CAPSULE, LIQUID FILLED | 25013165 | REK4960K2U | 4mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | CONCENTRATE | 25013165 | REK4960K2U | 0.08mg/1ml | ||
BUTYLATED HYDROXYANISOLE | ORAL | GRANULE, FOR SUSPENSION | 25013165 | REK4960K2U | NA | ||
BUTYLATED HYDROXYANISOLE | ORAL | LIQUID | 25013165 | REK4960K2U | 8mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | SOLUTION | 25013165 | REK4960K2U | 5mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | SUSPENSION | 25013165 | REK4960K2U | 2.5mg/5ml | ||
BUTYLATED HYDROXYANISOLE | ORAL | SYRUP | 25013165 | REK4960K2U | 0.5mg/5ml | ||
BUTYLATED HYDROXYANISOLE | ORAL | TABLET | 25013165 | REK4960K2U | 8mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | TABLET, EXTENDED RELEASE | 25013165 | REK4960K2U | 1mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | TABLET, FILM COATED | 25013165 | REK4960K2U | 0.4mg | ||
BUTYLATED HYDROXYANISOLE | ORAL | TABLET, ORALLY DISINTEGRATING | 25013165 | REK4960K2U | 2mg | ||
BUTYLATED HYDROXYANISOLE | RECTAL | SUPPOSITORY | 25013165 | REK4960K2U | 0.21mg | ||
BUTYLATED HYDROXYANISOLE | SUBLINGUAL | FILM | 25013165 | REK4960K2U | 0.08mg | ||
BUTYLATED HYDROXYANISOLE | SUBLINGUAL | TABLET | 25013165 | REK4960K2U | 2mg | ||
BUTYLATED HYDROXYANISOLE | TOPICAL | CREAM | 25013165 | REK4960K2U | 5.2%w/w | ||
BUTYLATED HYDROXYANISOLE | TOPICAL | GEL | 25013165 | REK4960K2U | 7mg | ||
BUTYLATED HYDROXYANISOLE | TOPICAL | LOTION | 25013165 | REK4960K2U | NA | ||
BUTYLATED HYDROXYANISOLE | TOPICAL | OINTMENT | 25013165 | REK4960K2U | 0.01%w/w | ||
BUTYLATED HYDROXYANISOLE | VAGINAL | CREAM | 25013165 | REK4960K2U | 0.03%w/w | ||
BUTYLATED HYDROXYANISOLE | VAGINAL | OINTMENT | 25013165 | REK4960K2U | 0.02%w/w | ||
BUTYLATED HYDROXYANISOLE | VAGINAL | SUPPOSITORY | 25013165 | REK4960K2U | 1mg | ||
BUTYLATED HYDROXYTOLUENE | BUCCAL | GUM, CHEWING | 128370 | 1P9D0Z171K | 5mg | ||
BUTYLATED HYDROXYTOLUENE | INTRAVENOUS | INJECTION | 128370 | 1P9D0Z171K | NA | ||
BUTYLATED HYDROXYTOLUENE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 128370 | 1P9D0Z171K | NA | ||
BUTYLATED HYDROXYTOLUENE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 128370 | 1P9D0Z171K | 0.02mg | ||
BUTYLATED HYDROXYTOLUENE | INTRAVENOUS | INJECTION, SOLUTION | 128370 | 1P9D0Z171K | NA | ||
BUTYLATED HYDROXYTOLUENE | NASAL | SPRAY, METERED | 128370 | 1P9D0Z171K | 0.1mg/1ml | ||
BUTYLATED HYDROXYTOLUENE | ORAL | CAPSULE | 128370 | 1P9D0Z171K | 1mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | CAPSULE, LIQUID FILLED | 128370 | 1P9D0Z171K | 0.1mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | FILM, SOLUBLE | 128370 | 1P9D0Z171K | 0.06mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | SOLUTION | 128370 | 1P9D0Z171K | 0.19mg/1ml | ||
BUTYLATED HYDROXYTOLUENE | ORAL | SOLUTION, CONCENTRATE | 128370 | 1P9D0Z171K | 0.1mg/1ml | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET | 128370 | 1P9D0Z171K | 3mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET, EXTENDED RELEASE | 128370 | 1P9D0Z171K | 1mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET, FILM COATED | 128370 | 1P9D0Z171K | 1mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 128370 | 1P9D0Z171K | 0.24mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET, FOR SUSPENSION | 128370 | 1P9D0Z171K | 0.1mg | ||
BUTYLATED HYDROXYTOLUENE | ORAL | TABLET, ORALLY DISINTEGRATING | 128370 | 1P9D0Z171K | 1mg | ||
BUTYLATED HYDROXYTOLUENE | RECTAL | SUPPOSITORY | 128370 | 1P9D0Z171K | 0.21mg | ||
BUTYLATED HYDROXYTOLUENE | SUBLINGUAL | TABLET | 128370 | 1P9D0Z171K | 0.13mg | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | AEROSOL | 128370 | 1P9D0Z171K | 0.1%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | AEROSOL, FOAM | 128370 | 1P9D0Z171K | 4mg | Y | |
BUTYLATED HYDROXYTOLUENE | TOPICAL | CREAM | 128370 | 1P9D0Z171K | 1mg | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | CREAM, AUGMENTED | 128370 | 1P9D0Z171K | 0.2%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL | 128370 | 1P9D0Z171K | 8mg | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL, METERED | 128370 | 1P9D0Z171K | 4mg | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | LOTION | 128370 | 1P9D0Z171K | 1000mg | Y | |
BUTYLATED HYDROXYTOLUENE | TOPICAL | OINTMENT | 128370 | 1P9D0Z171K | 0.1%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | SHAMPOO | 128370 | 1P9D0Z171K | 0.1%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | SOAP | 128370 | 1P9D0Z171K | 0.02%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | SOLUTION | 128370 | 1P9D0Z171K | 3mg | Y | |
BUTYLATED HYDROXYTOLUENE | TOPICAL | SPRAY | 128370 | 1P9D0Z171K | 3mg | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | SUSPENSION | 128370 | 1P9D0Z171K | 0.02%w/w | ||
BUTYLATED HYDROXYTOLUENE | TOPICAL | SWAB | 128370 | 1P9D0Z171K | 0.5%w/w | ||
BUTYLATED HYDROXYTOLUENE | VAGINAL | CREAM | 128370 | 1P9D0Z171K | 0.05%w/w | ||
BUTYLATED HYDROXYTOLUENE | VAGINAL | SUPPOSITORY | 128370 | 1P9D0Z171K | NA | ||
BUTYLENE GLYCOL | TOPICAL | SYSTEM | 107880 | 3XUS85K0RA | 1400mg | ||
BUTYLENE GLYCOL | TRANSDERMAL | SYSTEM | 107880 | 3XUS85K0RA | 8.12mg | ||
BUTYLPARABEN | OPHTHALMIC | SOLUTION | 94268 | 3QPI1U3FV8 | 0.02%w/w | ||
BUTYLPARABEN | ORAL | CAPSULE | 94268 | 3QPI1U3FV8 | NA | ||
BUTYLPARABEN | ORAL | CAPSULE, EXTENDED RELEASE | 94268 | 3QPI1U3FV8 | NA | ||
BUTYLPARABEN | ORAL | DROPS | 94268 | 3QPI1U3FV8 | NA | ||
BUTYLPARABEN | ORAL | SOLUTION | 94268 | 3QPI1U3FV8 | 6mg | ||
BUTYLPARABEN | ORAL | SUSPENSION | 94268 | 3QPI1U3FV8 | 12mg | ||
BUTYLPARABEN | ORAL | SYRUP | 94268 | 3QPI1U3FV8 | 28.4mg/1ml | ||
BUTYLPARABEN | ORAL | TABLET | 94268 | 3QPI1U3FV8 | NA | ||
BUTYLPARABEN | ORAL | TABLET, COATED | 94268 | 3QPI1U3FV8 | 0.08mg | ||
BUTYLPARABEN | ORAL | TABLET, EXTENDED RELEASE | 94268 | 3QPI1U3FV8 | 0.01mg | ||
BUTYLPARABEN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 94268 | 3QPI1U3FV8 | NA | ||
BUTYLPARABEN | RECTAL | SOLUTION | 94268 | 3QPI1U3FV8 | 0.01%w/v | ||
BUTYLPARABEN | TOPICAL | CREAM | 94268 | 3QPI1U3FV8 | 0.4%w/w | ||
BUTYLPARABEN | TOPICAL | LIQUID | 94268 | 3QPI1U3FV8 | 0.02%w/w | ||
BUTYLPARABEN | TOPICAL | LOTION | 94268 | 3QPI1U3FV8 | 4mg | ||
BUTYLPARABEN | TOPICAL | OINTMENT | 94268 | 3QPI1U3FV8 | 0.18%w/w |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024